The government puts a stop to ‘ghost’ pharmaceutical companies
It seems that the anti-corruption mode is activated in earnest. In a move that reminds us of when your friend owes you money and suddenly stops answering your messages, President Claudia Sheinbaum has just announced that several pharmaceutical companies are on the bench. Literally. These companies, which apparently confused contracts with the federal government with suggested and non-mandatory options, now face administrative procedures that will leave them out of the next drug tender. Basically, they gave them the plane and now they were left without a party.
All this is the outcome of an ultimatum launched in September, an institutional “either they comply or we kill them”, directed at 32 companies that were conspicuous by their absence when it came to delivering the promised drugs. They were given until the end of the month to catch up, but some, in an act of pure main character energy, decided the rules didn’t apply to them. The government’s response was immediate: the Anti-Corruption and Good Government Secretariat entered the scene with all the sanctioning paraphernalia. A true plot twist that no one saw coming.
The corporate ‘and you more’ that didn’t work
In a plot twist worthy of an afternoon soap opera, the accused companies attempted the classic counterattack: they alleged that the public administration owed them payments. But, spoiler alert: that strategy did not work out well for them. Sheinbaum, with the calm of someone who already has the cards marked, was clear in her morning conference: “A number of companies will no longer be able to participate… all the administrative procedures are being carried out.” In other words, they applied the “sorry, next” message at the government level. The person in charge of coming forward and presenting the list of laboratories on the blacklist will be none other than the head of the Anti-Corruption Secretariat, Raquel Buenrostro, who will soon make her revelation, like the top 10 of anime betrayals, but in a formal suit.
The underlying message is clear: in this administration, supply contracts are not mere bureaucratic procedures. This is a public health issue where corporate excuses have no place. The measure seeks, in essence, to shield the health system from the whims of the pharmaceutical industry and to guarantee that treatments and medical supplies reach the patients who need them, without the non-compliance that has so characterized this sector in the past.
A watershed in the purchase of medicines
The impact of these exemplary sanctions goes beyond the punishment of a few companies. We are facing a paradigm shift in the relationship between the State and providers of medical supplies. Sheinbaum noted that Buenrostro will present the information “once these companies have already been sanctioned,” which suggests that the process is already underway and is irreversible. This zero tolerance policy seeks to set a strong precedent: failure to deliver essential medications will have direct consequences on the ability of companies to continue doing business with the government.
The ultimate goal is ambitious: to eradicate the chronic shortage that has plagued hospitals and clinics for years, ensuring that patients receive their treatments on time. It is a commitment to reconfigure the entire drug supply chain, prioritizing collective well-being over the commercial interests of a few. In a country where access to health is a constitutional right, these kinds of republican austerity and accountability measures are not only welcome, but necessary. They represent a firm step towards the construction of a more robust, transparent and, above all, reliable national health system.
Do you think these sanctions will mark a before and after in the purchase of medicines?Share this note and help us make the information viral so that more people know about these measures that directly impact public health.Explore more content related to health policies and transparency on our site.
